IRIS
LARONI, ALICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.401
AS - Asia 1.612
NA - Nord America 1.378
Continente sconosciuto - Info sul continente non disponibili 389
SA - Sud America 135
AF - Africa 32
OC - Oceania 1
Totale 14.948
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 11.161
US - Stati Uniti d'America 1.290
SG - Singapore 616
CN - Cina 415
VN - Vietnam 253
BD - Bangladesh 159
FR - Francia 103
BR - Brasile 79
HK - Hong Kong 46
CA - Canada 30
AR - Argentina 27
DE - Germania 26
MX - Messico 26
FI - Finlandia 24
IQ - Iraq 18
JP - Giappone 17
GB - Regno Unito 14
NL - Olanda 14
ES - Italia 13
IN - India 13
CH - Svizzera 12
ID - Indonesia 10
JM - Giamaica 10
PH - Filippine 9
PK - Pakistan 9
CR - Costa Rica 7
EC - Ecuador 6
KE - Kenya 6
ZA - Sudafrica 6
CL - Cile 5
PY - Paraguay 5
TR - Turchia 5
UA - Ucraina 5
AZ - Azerbaigian 4
IE - Irlanda 4
KR - Corea 4
MA - Marocco 4
NI - Nicaragua 4
SA - Arabia Saudita 4
BO - Bolivia 3
CO - Colombia 3
DZ - Algeria 3
JO - Giordania 3
LT - Lituania 3
OM - Oman 3
PE - Perù 3
RS - Serbia 3
RU - Federazione Russa 3
SC - Seychelles 3
TH - Thailandia 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
BH - Bahrain 2
DO - Repubblica Dominicana 2
HN - Honduras 2
HR - Croazia 2
IL - Israele 2
KZ - Kazakistan 2
MY - Malesia 2
NP - Nepal 2
PR - Porto Rico 2
RO - Romania 2
SI - Slovenia 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
AT - Austria 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BG - Bulgaria 1
BS - Bahamas 1
CG - Congo 1
CV - Capo Verde 1
EE - Estonia 1
EG - Egitto 1
GA - Gabon 1
GF - Guiana Francese 1
GT - Guatemala 1
HT - Haiti 1
HU - Ungheria 1
IR - Iran 1
KG - Kirghizistan 1
LB - Libano 1
LU - Lussemburgo 1
MM - Myanmar 1
MN - Mongolia 1
PL - Polonia 1
PS - Palestinian Territory 1
PT - Portogallo 1
SE - Svezia 1
SL - Sierra Leone 1
SO - Somalia 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
UZ - Uzbekistan 1
VC - Saint Vincent e Grenadine 1
YT - Mayotte 1
Totale 14.561
Salva come PNG Salva come JPEG
Città #
Genova 5.668
Genoa 3.522
Vado Ligure 967
Rapallo 781
San Jose 378
Singapore 266
Ashburn 141
Lauterbourg 94
Ho Chi Minh City 83
Beijing 76
Hanoi 53
New York 46
Hong Kong 42
Council Bluffs 32
Santa Clara 32
Los Angeles 25
Milan 25
Frankfurt am Main 24
Helsinki 24
Bordighera 20
Rome 19
Mexico City 18
Tokyo 15
Chicago 14
Haiphong 13
Buffalo 12
St Louis 12
Boardman 11
Bar Harbor 10
Philadelphia 10
São Paulo 10
Washington 10
Dallas 9
Jacksonville 9
Miami 9
Bari 8
Da Nang 8
Kingston 8
Naples 8
Toronto 8
Amsterdam 7
Biên Hòa 7
Denver 7
Zurich 7
Brunswick 6
Guangzhou 6
Johannesburg 6
Madrid 6
Montreal 6
Nairobi 6
Tianjin 6
Des Moines 5
Karachi 5
Palermo 5
Paris 5
Rio de Janeiro 5
San Francisco 5
San José 5
Santiago 5
Turin 5
Walled Lake 5
Albuquerque 4
Baku 4
Baltimore 4
Bologna 4
Dublin 4
Hải Dương 4
Karbala 4
Las Vegas 4
Managua 4
Nashville 4
Ninh Bình 4
The Bronx 4
Amman 3
Atlanta 3
Baghdad 3
Belgrade 3
Brooklyn 3
Can Tho 3
Caracas 3
Cardiff 3
Changsha 3
Chennai 3
Cleveland 3
Colonia 3
Fayetteville 3
Hangzhou 3
Houston 3
Jakarta 3
Miano 3
Orem 3
Orlando 3
Plano 3
Queens 3
Quảng Ngãi 3
Raleigh 3
Richmond 3
Roseville 3
Salem 3
Sorocaba 3
Totale 12.769
Salva come PNG Salva come JPEG
Nome #
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS 270
Finger motor performance as a new quantitative clinical endpoint in multiple sclerosis 247
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy 244
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. 221
Neuroprotective features of mesenchymal stem cells. 220
Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis 220
Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. 218
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption 215
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma 207
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. 204
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study 196
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 192
A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study 182
Teriflunomide treatment reduces B cells in patients with MS. 180
Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. 178
Hypothalamic AgRP neurons control hematopoiesis and lymphopoiesis and are activated in experimental MS 176
A case of thyroiditis during natalizumab therapy for multiple sclerosis 175
Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod 173
Three years of experience: the Italian registry and safety data update 171
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis 170
T-cell trafficking in the central nervous system. 169
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. 164
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases 163
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 163
Approved drugs for multiple sclerosis: The challenge of choice 162
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. 161
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy 159
JCV-DNA testing during natalizumab treatment is complementary to anti-JCV antibodies for PML risk stratification 155
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 155
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 155
Mesenchymal stem cells as treatment for MS - progress to date. 151
Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation 151
Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report 150
Unraveling the regulatory role of NK cells on T-cell effector functions: Implications for CNS autoimmunity 146
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. 146
Role of the innate immune system in the pathogenesis of multiple sclerosis. 144
Can we kill an extra bird with the same stone? 143
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 143
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome 141
Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab 141
Do NK cells play a role in the possible association between natalizumab treatment and the development of melanoma? 140
Regulatory Functions of Natural Killer Cells in Multiple Sclerosis 139
Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution 138
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis 137
Wernicke's syndrome during parenteral feeding: not an unusual complication. 136
The short-chain fatty acid butyrate decreases the regulatory function of human natural killer cells and promotes their maturation 135
Assessing upper limb function in Multiple Sclerosis by an engineered glove 134
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study 132
IL-27 imparts immunoregulatory function to human NK cell subsets. 131
A pilot study comparing myelin measurements from [18F]-Florbetaben PET and quantitative T1 map imaging in multiple sclerosis (MS) 130
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study 129
The early effect of cladribrine versus fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis 128
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 128
Dysregulation of regulatory CD56 (bright) NK cells/T cells interactions in multiple sclerosis 125
Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy 125
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study 125
Long-term disability progression in primary progressive multiple sclerosis: A 15-year study 123
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 122
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 121
The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL 120
Epstein-Barr-negative MS: a true phenomenon? 119
Natural killer cells are functionally defective in multiple sclerosis 118
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks 117
Health-related quality of life in multiple sclerosis: Effects of natalizumab 115
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis 115
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis 114
Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy. 114
Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system. 111
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks 111
Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey 110
Impaired suppressor function of NK cells in multiple sclerosis 109
Aging with multiple sclerosis: Clinical characterization of an elderly population, a cross-sectional study 108
Interferon beta potentiates the therapeutic activity of mesenchymal stem cells 106
Noradrenergic control of bone marrow and thymus by AgRP neurons is impaired in experimental multiple sclerosis 103
Enhancing natural killer cells is beneficial in multiple sclerosis - Yes 102
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: who gains from it? 101
Effect of ocrelizumab treatment on retinal atrophy: preliminary results from a single-center observational study 99
Tailoring B cell depletion therapy in MS according to memory B cell monitoring 98
Impaired suppressor function of CD56bright NK cells in early multiple sclerosis 97
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 97
Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? 97
Beyond steady-state amyloid PET to detect demyelination in multiple sclerosis (MS) 97
Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups 96
A real-world study of alemtuzumab in a cohort of Italian patients 96
The effect of Cladribine and Fingolimod treatments on retinal atrophy 95
COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments 95
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies 93
Multivariate clinically isolated syndrome (CIS) risk factor study: towards individual prognosis and treatment indication in CIS 92
CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis 92
Mesenchymal stem cells for multiple sclerosis: effect of treatment on peripheral immune cells 90
MESEMS: a randomized, double blind placebo-controlled cross-over study to evaluate safety and efficacy of intravenous administration of autologous mesenchymal stem cells in patients with multiple sclerosis 90
Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection 87
Nonfunctional natural killer regulatory cells in multiple sclerosis 82
Effect of SARS-CoV-2 vaccination on natural killer cell responses in multiple sclerosis 81
Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives 77
Family Functioning and Multiple Sclerosis: preliminary data of a Multicentric Italian Project 76
Relapsing meningitis and limbic encephalitis in anti-AQP4-Ab-associated neuromyelitis optica spectrum disorder 74
Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review 74
To switch therapies in RRMS: why and when? A real-life multicentre study. 74
Ageing with MS: a cross sectional study 73
Totale 13.614
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.866
article - articoli 51.016
book - libri 0
conference - conferenze 496
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 354
Totale 103.732
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.094 45 28 84 111 44 94 40 252 74 113 66 143
2022/2023960 99 74 15 78 149 163 6 67 171 15 102 21
2023/2024765 41 84 9 88 66 84 53 70 69 18 46 137
2024/20252.508 104 214 96 158 294 293 262 421 121 138 183 224
2025/20264.338 510 114 244 388 538 343 592 247 268 432 269 393
2026/2027446 446 0 0 0 0 0 0 0 0 0 0 0
Totale 14.948